RPM Act of 2019

Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D prescription drug benefits S.652 - Safe Step Act S.1038 - Drug Price Transparency in Medicaid Act S.1130 - Health Care PRICE Transparency Act S.1131 - Drug Price Transparency Act S.1217 - Ending the Prescription Drug Kickback Act S.1375 - HELP Copays Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act S.2254 - Medicare PBM Accountability Act S.2405 - Strengthening Pharmacy Access for Seniors Act S.2406 - PBM Oversight Act S.2408 - IMPROVE Part D Regulations Act S.2436 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act S.2456 - Protecting Seniors from High Drug Costs Act S.2474 - Share the Savings with Seniors Act S.2477 - Equitable Community Access to Pharmacist Services Act S.2493 - PBM Reporting Transparency Act S.2939 - Pharmacy Access Oversight and Reporting Act S.2973 - Modernizing and Ensuring PBM Accountability Act H.R.830 - HELP Copays Act H.R.1352 - Increasing Access to Biosimilars Act H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacists Act H.R.2630 - Safe Step Act H.R.2666 - Medicaid VBPs for Patients (MVP) Act H.R.2670 - PBM Accountability Act H.R.2691 - Transparent PRICE Act H.R.2880 - Protecting Patients Against PBM Abuses Act H.R.3262 - to amend title XI of the Social Security Act to increase transparency of certain health-related ownership information H.R.3281 - Transparent PRICE Act H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3285 - Fairness for Patient Medications H.R.3561- Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R.4011 - Timely Access to Clinical Treatment Act H.R.4881 - To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program H.R.4883 - Medicare Common Ownership Transparency Act H.R.5372 - Expanding Seniors Access to Lower Cost Medicines Act H.R.5376 - Share the Savings with Seniors Act H.R.5378 - Lower Costs More Transparency Act H.R.5384 - Advancing Enrollment and Reducing Drug Costs Act H.R.5385 - Medicare PBM Accountability Act H.R.5386 - Cutting Copays Act H.R.5393-Transparency and Fairness for Pharmacies Act H.R.5400 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act H.R.5461 - Ensuring Access to Lower-Cost Medicines for Seniors Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation

Client expense: $3,973,758 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D prescription drug benefits H.R.2666 -- Medicaid MVP for Patients Act S.652 / H.R.2630 -- Safe Step Act H.R.2679 -- Pharmacy Benefits Manager Accountability Act H.R.2691 - Transparent PRICE Act H.R.3281 - Transparent PRICE Act H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3285 - Fairness for Patient Medications Act H.R.3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act H.R.4011 - Timely Access to Clinical Treatment Act S.1038 / H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacist Services Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act S. 1375 / H.R.830 - Help Ensure Lower Patient (HELP) Copays Act H.R.1352 - Increasing Access to Biosimilars Act H.R.3799 - CHOICE Arrangement Act S.1130 - Health Care PRICE Transparency Act S.1131 - Drug Price Transparency Act H.R.3284 - Providers and Payers COMPETE Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration

Client expense: $3,402,542 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, pharmacy networks, and mail-service pharmacy S.113 - Prescription Pricing for the People Act S.127 - Pharmacy Benefit Manager Transparency Act H.R.2679 - Pharmacy Benefits Manager Accountability Act H.R.2691 - Transparent PRICE Act H.R.3281 - Transparent PRICE Act S.1339 - Pharmacy Benefit Manager Reform Act H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.1038 / H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacist Services Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act H.R.3284 - Providers and Payers COMPETE Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration

Client expense: $3,402,542 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to prescription drug coverage and pharmacy benefits Issues related to the prescription drug marketplace, patents, and competition Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits S.113 - Prescription Pricing for the People Act S.127 - Pharmacy Benefit Manager Transparency Act H.R.2666 - Medicaid MVP for Patients Act S.652 / H.R.2630 - Safe Step Act H.R.2679 - Pharmacy Benefits Manager Accountability Act H.R.2691 - Transparent PRICE Act H.R.3281 - Transparent PRICE Act S.1339 - Pharmacy Benefit Manager Reform Act S.1543 - A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third party administration services H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3285 - Fairness for Patient Medications Act H.R.3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act H.R.4011 - Timely Access to Clinical Treatment Act S.1038 / H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacist Services Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act S. 1375 / H.R.830 - Help Ensure Lower Patient (HELP) Copays Act S.954 / H.R.1488 - Affordable Insulin Now Act H.R.1503 - Prescription Information Modernization Act H.R.1352 - Increasing Access to Biosimilars Act S.1374 - Patient Right to Shop Act H.R.3799 - CHOICE Arrangement Act S.142 - Preserve Access to Affordable Generics and Biosimilars Act S.148 - Stop STALLING Act S.150 - Affordable Prescriptions for Patients Act S.574 - Increasing Prescription Drug Competition Act S.775 - Increasing Transparency in Generic Drug Applications Act H.R.1790 - Biologics Competition Act S.1067 - Ensuring Timely Access to Generics Act S.1114 - Expanding Access to Low-Cost Generics Act S.1120 - Improved Access to Affordable Medications Act S.1128 - Ensuring Access to Generic Medications Act S.1522 - A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable S.1130 - Health Care PRICE Transparency Act S.1131 - Drug Price Transparency Act H.R.3284 - Providers and Payers COMPETE Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration

Client expense: $3,402,542 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 830/ S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2500: Protecting Americans from Unsafe Drugs Act of 2023 H.R. 2679: Pharmacy Benefit Manager Accountability Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2940/S 1355 PASTEUR Act/Incentives to increase novel antibiotic medicines H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3008: Drug Shortage Prevention Act of 2023 H.R. 3281: Transparent PRICE Act H.R. 3285: Fairness for Patient Medications Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program/Transparency Legislation H.R. 3433: Give Kids a Chance Act of 2023 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3791: Improving DATA in Public Health Act H.R. 3793: Ensuring Access to Lifesaving Drugs Act of 2023 H.R. 3810: Drug Origin Transparency Act of 2023 H.R. 4390: Protect 340B Act - Provisions related to 340B Program (117th Congress) H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169)/Implementation of $0 Vaccine co-pay; maximum fair price provisions H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022 - This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why) (117th Congress) H.R. 7653: Modern Authentication of Pharmaceuticals Act of 2022 (117th Congress) S. 6: Biosimilar Red Tape Elimination Act (117th Congress) S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes. S. 476: Maintaining Investments in New Innovation Act S. 775: Increasing Transparency in Generic Drug Applications Act S. 1128: Ensuring Access to Generic Medications Act S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021 - Provisions related to drug pricing (117th Congress) S. 1967: Patients Before Middlemen (PBM Act) S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1114: Expanding Access to Low-Cost Generics Act 2023 S. 1214: RARE Act - To set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1355: PASTEUR Act of 2023 - Provisions related to antimicrobial resistance policy issues S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act (117th Congress) Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Mental health policy issues High deductible health plans/HSA policy issues Supply chain policy issues Real world evidence policy issues Clinical trial diversity policy issues Prescription drug abuse policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues COVID-19 policy issues Pandemic preparedness policy issues Defense Production Act policy issues Cybersecurity policy issues Anticounterfeiting policy issues Chronic Kidney Disease Improvement in Research and Treatment Act. H.R.2534 - PROTECT 340B Act of 2023 House Draft Language for PAHPA Reauthorization HR 3665 - Defending American Jobs and Investment Act Senate Draft Language for PAHPA Reauthorization Pandemic and All Hazards Preparedness Act reauthorization (discussion draft) Labor HHS appropriations (ongoing discussion) Under Taxed Profit Rule, Ways and Means Committee discussion Vaccine Injury Compensation Program reform discussion

Client expense: $900,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2500: Protecting Americans from Unsafe Drugs Act of 2023 H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefit Manager Accountability Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3008: Drug Shortage Prevention Act of 2023 H.R. 3281: Transparent PRICE Act H.R. 3285: Fairness for Patient Medications Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2023 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3791: Improving DATA in Public Health Act H.R. 3793: Ensuring Access to Lifesaving Drugs Act of 2023 H.R. 3810: Drug Origin Transparency Act of 2023 H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169) H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022 (117th Congress) H.R. 7653: Modern Authentication of Pharmaceuticals Act of 2022 (117th Congress) S. 6: Biosimilar Red Tape Elimination Act (117th Congress) S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes S. 476: Maintaining Investments in New Innovation Act S. 775: Increasing Transparency in Generic Drug Applications Act S. 1128: Ensuring Access to Generic Medications Act S. 935: Fair Accountability and Innovative Research Drug Pricing Act of 2023 - Provisions related to drug pricing S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1114: Expanding Access to Low-Cost Generics Act 2023 S. 1214: RARE Act - To set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1355: PASTEUR Act of 2023 - Provisions related to antimicrobial resistance policy issues S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act (117th Congress) Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Mental health policy issues High deductible health plans/HSA policy issues Supply chain policy issues Real world evidence policy issues Clinical trial diversity policy issues Prescription drug abuse policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues COVID-19 policy issues Pandemic preparedness policy issues Defense Production Act policy issues Cybersecurity policy issues Anticounterfeiting policy issues

Client expense: $6,300,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Legislative End of National Emergency (COVID-19) - H.J.Res.7, Public Law No: 118-3 Coverage of recommended preventative services -Affordable Care Acts (ACA) preventative services requirement, Braidwood v. Becerra ruling Pharmacy Benefit Manager (PBM) legislation including the PBM Reform Act - S. 1339 Safe Step Act - S. 652 Site-Based Invoicing and Transparency Enhancement (SITE) Act - S. 1869 Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 - H.R. 3561 Transparent PRICE Act - H.R. 3281 Fairness for Patients Medications Act - H.R. 3285 Facilitating Accountability in Reimbursements Act (FAIR Act) - H.R. 3417 Chronic Disease Flexible Coverage Act - H.R. 3800 Mental Health Matters Act - (H.R. 7780) (117th Congress) Health Network and Directory Improvement Act - S. 5093 Healthcare Workforce Shortage - request for information (RFI), Senate Health, Education, Labor and Pensions (HELP) Committee Healthy Competition for Better Care Act - S. 3139 (118th Congress) Telehealth Expansion Act - S, 1001/H.R. 1843 HSA Telehealth Extension Telehealth Benefit Expansion for Workers Act - H.R. 824 Employer-sponsored health coverage Site-Neutral Payment Reform Hospital Billing Practices Mental health parity Health cost transparency Dependent Care Flexible Spending Accounts (FSAs) Health Flexible Spending Accounts (FSAs) Health Savings Accounts (HSAs) Chronic Disease Management Prescription drug legislation Surprise billing regulations Health Equity ERISA preemption Regulatory White House - End of Public Health Emergency (PHE) and National Emergency (NE) Department of Health (HHS), Department of Labor (Labor) and Department of Treasury (Treasury) - (the tri-agencies) - guidance issued on end of COVID-19 Public Health Emergency (PHE) and National Emergency (NE) Centers for Medicare and Medicaid Services (CMS) - comment letter underscoring importance of Medicare Advantage to employers and comments on 2024 rate notice HHS and CMS - request for information (RFI) - current essential health benefits guidance HHS, Labor and Treasury(the tri-agencies) - guidance on group health plan attestations to Gag clause prohibition HHS, Labor and Treasury(the tri-agencies) -clarification of air ambulance reporting deadline for group health plans HHS, Labor and Treasury(the tri-agencies) - prescription drug and health care cost reporting - submitted comments HHS, Labor and Treasury (the tri-agencies) - final surprise billing regulations on the independent dispute resolution (IDR) process HHS, Labor and Treasury (the tri-agencies) - request for information (RFI) - advanced explanation of benefits Treasury/IRS -Pre-Deductible Telehealth Care in High Deductible Health Plans HHS, Labor and Treasury (the tri-agencies) Mental health parity requirements for group health plans and insurers, including under the CAA HHS, Labor and Treasury (tri-agencies) - transparency provisions under the CAA HHS - Enforcement of Hospital Price Transparency Rules Treasury/IRS - request for guidance on repurposing of welfare benefit fund assets ERISA uniformity High Deductible Health Plans (HDHPs) Health Savings Accounts (HSAs) State health care requirements affecting self-insured plans Abortion coverage and travel benefits in health plans Employer mandate ERISA Preemption Preventative care

Client expense: $440,980 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Equal Employment Opportunity Commission (EEOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office

PBM Transparency-Issues concerning PBM reporting of rebates and payments through the pharmaceutical supply chain. S. 127, The Pharmacy Benefit Manager Transparency Act of 2023," provisions related to the Federal Trade Commission regulation of PBMs. H.R. 4011, Timely Access to Clinical Treatment (TACT) Act of 2023, provisions on pharmacy access standards. Issues related to cost-sharing for insulin and other therapies in the commercial market. S. 1339, the Pharmacy Benefit Manager Reform Act provisions related to PBM disclosure, fee pass through and fee structures. H.R. 3862, Improving Transparency to Lower Drug Cost Act of 2021 (117th Congress)-provisions related to PBM transparency and disclosure. H.R. 3561, The PATIENT Act, provisions related to disclosure of drug price concessions and highly-rebated drugs. H.R. 37999, the CHOICE Act, potential amendments related to PBM pharmacy contracting practices. Issues related to patient cost-sharing and drug coupons. H.R. 3281/H.R. 2681, The Transparence PRICE Act, issues related to disclosure of drug price concessions. H.R. 2679, Pharmacy Benefit Manager Accountability Act, provisions related to client disclosure of drug price concessions particularly coupon use.

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Recognizing the Protection of Motorsports Act (HR 3281) (SB 2736) Inflation Reduction Act of 2022

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Educated members of Congress on vehicle fuel efficiency and greenhouse gas emissions. Educated members of Congress and the Administration on the impact of the Cleaner Trucks Initiative and heavy-duty NOx emissions. HR 3281/S. 2736 - RPM Act

Client expense: $130,000 · Firm income: Not reported

Government targets: Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)

Motor Vehicle Safety. Infrastructure Investment. H.R.4521 - America COMPETES Act of 2022. H.R.7900 - National Defense Authorization Act for Fiscal Year 2023. H.R.2617 - Consolidated Appropriations Act, 2023. H.R.3281/S.2736 - Protection of Motorsports Act of 2021 or the RPM Act of 2021.

Client expense: $150,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Labor, Dept of (DOL), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, White House Office

H.R. 3281 - RPM Act. Would clarify that the conversion of street certified vehicles into competition use only vehicles is not prohibited by the Clean Air Act. H.R. 5376 Inflation Reduction Act. Eliminated tax credit for the purchase of an electric motorcycle.

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1512, Clean Future Act H.R. 2617, Consolidated Appropriations Act, 2023 S. 2385, Corn Ethanol Mandate Elimination Act S. 2736/ H.R. 3281, Recognizing the Protection of Motorsports Act (RPM Act)

Client expense: $240,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Recognizing the Protection of Motorsports (RPM) Act of 2021 (H.R.3281/S. 2736)

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1512, Clean Future Act S. 2385, Corn Ethanol Mandate Elimination Act S. 2736/ H.R. 3281, Recognizing the Protection of Motorsports Act (RPM Act)

Client expense: $245,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Educated members of Congress on vehicle fuel efficiency and greenhouse gas emissions. Educated members of Congress and the Administration on the impact of the Cleaner Trucks Initiative and heavy-duty NOx emissions. HR 3281/S. 2736 - RPM Act

Client expense: $130,000 · Firm income: Not reported

Government targets: Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)

Recognizing the Protection of Motorsports Act (HR 3281) (SB 2736) Inflation Reduction Act of 2022

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 3281 and S.2736- Recognizing the Protection of Motorsports Act of 2021 or RPM Act of 2021

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3281 - RPM Act. Would clarify that the conversion of street certified vehicles into competition use only vehicles is not prohibited by the Clean Air Act. H.R. 5376 Inflation Reduction Act. Eliminated tax credit for the purchase of an electric motorcycle.

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Educated members of Congress on vehicle fuel efficiency and greenhouse gas emissions. Educated members of Congress and the Administration on the impact of the Cleaner Trucks Initiative and heavy-duty NOx emissions. HR 3281/S. 2736 - RPM Act

Client expense: $160,000 · Firm income: Not reported

Government targets: Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)

H.R. 1512, Clean Future Act S. 2385, Corn Ethanol Mandate Elimination Act S. 2736/ H.R. 3281, Recognizing the Protection of Motorsports Act (RPM Act)

Client expense: $270,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Recognizing the Protection of Motorsports Act (HR 3281) (SB 2736)

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

H.R. 3281 - RPM Act. Would clarify that the conversion of street certified vehicles into competition use only vehicles is not prohibited by the Clean Air Act.

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Recognizing the Protection of Motorsports Act (HR 3281) (SB 2736)

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1512, Clean Future Act S. 2385, Corn Ethanol Mandate Elimination Act S. 2736/ H.R. 3281, Recognizing the Protection of Motorsports Act (RPM Act)

Client expense: $245,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Educated members of Congress on vehicle fuel efficiency and greenhouse gas emissions. Educated members of Congress and the Administration on the impact of the Cleaner Trucks Initiative and heavy-duty NOx emissions. HR 3281/S. 2736 - RPM Act

Client expense: $160,000 · Firm income: Not reported

Government targets: Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

H.R. 3281 - RPM Act. Would clarify that the conversion of street certified vehicles into competition use only vehicles is not prohibited by the Clean Air Act.

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Educated members of Congress on vehicle fuel efficiency and greenhouse gas emissions. Educated members of Congress and the Administration on the impact of the Cleaner Trucks Initiative and heavy-duty NOx emissions. HR 3281/S. 2736 - RPM Act

Client expense: $160,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Transportation Safety Board (NTSB), Office of Management & Budget (OMB), SENATE, Small Business Administration (SBA), Transportation, Dept of (DOT), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR), Vice President of the U.S., White House Office

Recognizing the Protection of Motorsports Act (HR 3281) (SB 2736)

Client expense: Not reported · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

H.R. 1512, Clean Future Act S. 2385, Corn Ethanol Mandate Elimination Act S. 2736/ H.R. 3281, Recognizing the Protection of Motorsports Act (RPM Act)

Client expense: $260,000 · Firm income: Not reported

Government targets: Bureau of Land Management (BLM), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, Small Business Administration (SBA), U.S. Forest Service

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

Advocating for the Recognizing the Protection of Motorsports Act (S. 2736/ H.R. 3281).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

H.R.2141, S. 1853 - To direct the Secretary of Transportation to establish a Motorcyclist Advisory Council, and for other purposes. Would reestablish the Motorcyclist Advisory Council to provide US DOT with input on transportation issues of concern to motorcyclists. H.R. 3684 - INVEST in America Act. Would reauthorize the Motorcyclist Advisory Council, funding for NHTSA motorcyclist safety grants, provide for other highway safety programs. S. 2016, S. 1931 - Surface Transportation Investment Act of 2021. Would reauthorize funding for NHTSA motorcyclist safety grants, provide for other highway safety programs. H.R. 3711 - SELF DRIVE Act. Would provide for the regulation and implementation of automated vehicles. H.R. 3281 - RPM Act. Would clarify that the conversion of street certified vehicles into competition use only vehicles is not prohibited by the Clean Air Act.

Client expense: $90,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)

Recognizing the Protection of Motorsports Act (HR 3281) (SB 2736)

Client expense: Not reported · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

H.R. 1512, Clean Future Act S. 2385, Corn Ethanol Mandate Elimination Act S. 2736/ H.R. 3281, Recognizing the Protection of Motorsports Act (RPM Act)

Client expense: $220,000 · Firm income: Not reported

Government targets: Bureau of Land Management (BLM), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, Small Business Administration (SBA), U.S. Forest Service

Educated members of Congress on vehicle fuel efficiency and greenhouse gas emissions. Educated members of Congress and the Administration on the impact of the Cleaner Trucks Initiative and heavy-duty NOx emissions. HR 3281/S. 2736 - RPM Act

Client expense: $160,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Transportation Safety Board (NTSB), Office of Management & Budget (OMB), SENATE, Small Business Administration (SBA), Transportation, Dept of (DOT), U.S. Copyright Office, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR), Vice President of the U.S., White House Office

H.R.2141, S. 1853 - To direct the Secretary of Transportation to establish a Motorcyclist Advisory Council, and for other purposes. Would reestablish the Motorcyclist Advisory Council to provide US DOT with input on transportation issues of concern to motorcyclists. H.R. 3684 - INVEST in America Act. Would reauthorize the Motorcyclist Advisory Council, funding for NHTSA motorcyclist safety grants, provide for other highway safety programs. S. 2016, S. 1931 - Surface Transportation Investment Act of 2021. Would reauthorize funding for NHTSA motorcyclist safety grants, provide for other highway safety programs. H.R. 3711 - SELF DRIVE Act. Would provide for the regulation and implementation of automated vehicles. H.R. 3281 - RPM Act. Would clarify that the conversion of street certified vehicles into competition use only vehicles is not prohibited by the Clean Air Act.

Client expense: $90,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)